DOUGLAS LYNCH: Open Payments
NPI 1154745586 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,865 in 85 payments from 9 companies in 2025. Trend: 2023 $2,974 · 2024 $2,752 · 2025 $1,865
Food & beverage: $1,865
| Company | Payments | Amount |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 28 | $584 |
| Forte Bio-Pharma LLC | 19 | $525 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $327 |
| PROTEGA PHARMACEUTIALS INC | 11 | $232 |
| IBSA Pharma Inc. | 4 | $86 |
| SCILEX PHARMACEUTICALS INC. | 2 | $36 |
| ABBVIE INC. | 2 | $30 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| PFIZER INC. | 1 | $21 |
Products named: PROLATE, RELISTOR, Nucynta, ROXYBOND, Belbuca, XTAMPZA, Tirosint, ZTLido.
Industry payments across NV — which companies pay providers there.
